Innovent Announces Completion of First Participant Dosed in the Seventh Phase 3 Clinical Trial (GLORY-OSA) of Mazdutide in China
SAN FRANCISCO and SUZHOU, China, June 15, 2025 /PRNewswire/ -- Innovent Biologics, Inc. (Innovent) (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality medicines for the treatment of oncology, cardiovascular and metabolic, autoimmune, ophthalmology and other major disease areas, announced that the first participant has been successfully dosed in a Phase 3 clinical trial (GLORY-OSA) of mazdutide, a dual glucagon (GCG) and glucagon-like peptide-1 (GLP-1) receptor agonist, in Chinese participants with moderate-to-severe obstructive sleep apnea (OSA) and obesity (BMI ≥ 28 kg/m2). This is the seventh Phase 3 clinical study of mazdutide in China, continuing to explore its potential in managing obesity and a range of metabolic syndromes, with the aim of generating more comprehensive and high-quality evidence to support clinical application.
GLORY-OSA is a multicenter, randomized, open-label Phase 3 clinical study (NCT06931028) comparing the efficacy and safety of mazdutide 9mg versus placebo in Chinese participants with moderate-to-severe obstructive sleep apnea (OSA) and obesity (BMI ≥ 28 kg/m2).The primary endpoint is the change in apnea-hypopnea index (AHI) from baseline to Week 48.
Globally, an estimated 425 million people aged 30 to 69 live with moderate-to-severe OSA, with China bearing the highest burden at approximately 66 million cases[1]. However, the diagnosis rates remain critically low, with less than 1% in China and only 20% in the U.S.[2],[3] The condition disproportionately affects individuals living with obesity, with a prevalence of 40%, increasing to 80.5% among those undergoing bariatric surgery[4],[5]. OSA-associated co-morbidities, including hypertension, cardiac arrhythmias, stroke, and metabolic syndrome, are strongly correlated with OSA severity[6],[7].
Positive airway pressure (PAP) is the first-line treatment for OSA, and certain patients experience transformative benefits from PAP. Challenges exist, however, as many others are unable to accept or adhere to PAP treatment due to the burdensome nature of the therapy. Moreover, current evidence does not strongly support a direct link between PAP and improved cardiometabolic outcomes (e.g., mortality, hypertension, myocardial infarction, stroke)[8]. Recently, the FDA approved Zepbound® (tirzepatide), a dual GLP-1 and glucose-dependent insulinotropic polypeptide (GIP) agonist, as the first and only prescription medicine for moderate-to-severe OSA in adults with obesity[9]. There is currently no approved treatment for OSA in China[1], highlighting a significant unmet medical need. The literature suggests[10],[11],[12] that a 10% reduction in weight is associated with a 26% decrease in AHI, and that each 1-unit reduction in BMI corresponds to a 2-3 unit decrease in AHI. As such, weight loss medications have emerged as potential treatments for OSA.
Professor Tianpei Hong, the Principal Investigator of the Study, Peking University Third Hospital, stated, 'Patients with untreated OSA face significantly increased risks of cardiovascular diseases, metabolic disorders, neurocognitive decline, and traffic accidents. Their quality of life and labor capacity are often severely hampered. The OSA proportion of patients living with obesity is large and grows year after year. Despite this, an effective drug treatment regimen for OSA is lacking in China[13]. In our Phase 3 study GLORY-1[14], mazdutide showed good weight loss efficacy with multi-cardiovascular metabolism improvement, and a well-tolerated safety profile, which positions mazdutide as the world's first dual GCG/GLP-1 receptor targeted drug for patients with OSA and obesity. I will work closely with the GLORY-OSA research team to ensure the successful and high-quality completion of this study, with the ultimate goal of obtaining robust clinical evidence and expanding treatment options for Chinese patients with moderate-to-severe OSA and obesity.'
Dr. Lei Qian, Senior Vice President of Clinical Development at Innovent, stated, 'We have developed different doses and regimens of mazdutide to address the diverse treatment needs of patients with different indications. The development of mazdutide for OSA specifically targets the treatment needs of Chinese patients with moderate-to-severe OSA and obesity (BMI ≥ 28 kg/m2). In a Phase 2 study, mazdutide 9 mg achieved an 18.6 % weight loss compared to placebo, along with notable cardiovascular and metabolic benefits. The 9 mg regimen also features a simple titration schedule and a favorable safety profile. We are optimistic that the GLORY-OSA study will further validate mazdutide's powerful efficacy and good safety, and provide a promising pharmacologic alternative to PAP, the current standard of care for patients with moderate-to-severe OSA.'
About Mazdutide (IBI362)
Innovent entered into an exclusive license agreement with Eli Lilly and Company (Lilly) for the development and potential commercialization of OXM3 (also known as mazdutide), a GLP-1R and GCGR dual agonist, in China. As a mammalian oxyntomodulin (OXM) analogue, mazdutide may offer additional benefits beyond those of GLP-1 receptor agonists—such as promoting insulin secretion, lowering blood glucose and reducing body weight—by also activating the glucagon receptor to increase energy expenditure and improve hepatic fat metabolism. Mazdutide has demonstrated excellent weight loss and glucose-lowering effects in clinical studies. It has also shown benefits in reducing waist circumference, blood lipids, blood pressure, blood uric acid, liver enzymes, and liver fat content, as well as improving insulin sensitivity.
Currently, Mazdutide has two NDAs accepted for review by NMPA, including for:
Mazdutide is currently being evaluated in seven Phase 3 clinical studies, including:
Among these, GLORY-1, DREAMS-1, and DREAMS-2 have already met their primary endpoints and the other four studies are currently ongoing.
In addition, several new clinical studies of mazdutide are initiated or planned, including:
About Innovent
Innovent is a leading biopharmaceutical company founded in 2011 with the mission to empower patients worldwide with affordable, high-quality biopharmaceuticals. The company discovers, develops, manufactures and commercializes innovative medicines that target some of the most intractable diseases. Its pioneering therapies treat cancer, cardiovascular and metabolic, autoimmune and eye diseases. Innovent has launched 15 products in the market. It has 3 new drug applications under regulatory review, 4 assets in Phase III or pivotal clinical trials and 15 more molecules in early clinical stage. Innovent partners with over 30 global healthcare companies, including Eli Lilly, Sanofi, Incyte, LG Chem and MD Anderson Cancer Center.
Guided by the motto, 'Start with Integrity, Succeed through Action,' Innovent maintains the highest standard of industry practices and works collaboratively to advance the biopharmaceutical industry so that first-rate pharmaceutical drugs can become widely accessible. For more information, visit www.innoventbio.com, or follow Innovent on Facebook and LinkedIn.
Forward-looking statement
This news release may contain certain forward-looking statements that are, by their nature, subject to significant risks and uncertainties. The words 'anticipate', 'believe', 'estimate', 'expect', 'intend' and similar expressions, as they relate to Innovent Biologics ('Innovent'), are intended to identify certain of such forward-looking statements. The Company does not intend to update these forward-looking statements regularly.
These forward-looking statements are based on the existing beliefs, assumptions, expectations, estimates, projections and understandings of the management of the Company with respect to future events at the time these statements are made. These statements are not a guarantee of future developments and are subject to risks, uncertainties and other factors, some of which are beyond the Company's control and are difficult to predict. Consequently, actual results may differ materially from information contained in the forward-looking statements as a result of future changes or developments in our business, the Company's competitive environment and political, economic, legal and social conditions.
The Company, the Directors and the employees of the Company assume (a) no obligation to correct or update the forward-looking statements contained in this site; and (b) no liability in the event that any of the forward-looking statements does not materialise or turn out to be incorrect.
View original content: https://www.prnewswire.com/news-releases/innovent-announces-completion-of-first-participant-dosed-in-the-seventh-phase-3-clinical-trial-glory-osa-of-mazdutide-in-china-302481798.html
SOURCE Innovent Biologics
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Medscape
an hour ago
- Medscape
Fast Five Quiz: How Much Do You Know About Bell Palsy?
Bell palsy, or idiopathic facial paralysis, is the most common peripheral paralysis of the facial nerve (cranial nerve VII). Many cases of facial nerve paralysis have identifiable etiologies, such as stroke, Lyme disease, or Ramsay Hunt syndrome, but Bell palsy is, by definition, idiopathic in nature. How much do you know about Bell palsy and its management? Check your knowledge with this quick quiz. Type 2 diabetes is associated with several types of peripheral neuropathy, including Bell palsy. The prevalence of peripheral neuropathy among patients with type 2 diabetes has been calculated to be as high as 53.6%. In one retrospective cohort study, 33% of participants with Bell palsy had coexisting type 2 diabetes. Additionally, obesity might increase the risk for Bell palsy. Some studies have concluded that there is a slight female preponderance among patients with Bell palsy, whereas others have found no sex predilection. Even if female sex is not a risk factor, evidence suggests that Bell palsy is associated with pregnancy. The median age of onset is 40 years, and patient age < 15 years is not a risk factor. However, Bell palsy has been identified in children and even infants. Facial nerve trauma can certainly cause symptoms resembling Bell palsy, but Bell palsy is idiopathic and does not have a traumatic etiology. If these symptoms resulted from trauma, the diagnosis would be traumatic facial nerve palsy rather than Bell palsy. Learn more about Bell palsy epidemiology. Lagophthalmos, but not true eyelid ptosis, is a characteristic feature of Bell palsy. Symptoms of Bell palsy typically have a rapid onset, manifesting from 24 to 72 hours and often resolving or partially resolving within a few weeks to 3 months. In Bell palsy, facial paralysis is usually unilateral, and bilateral facial paralysis should lead to consideration and evaluation for other etiologies. Hearing loss is not a typical symptom of Bell palsy. The presence of hearing loss indicates an association with an upper motor neuron lesion or a lesion involving more than the facial nerve. Learn more about Bell palsy presentation. A rapid evidence review on Bell palsy points out that, as the condition is idiopathic, laboratory diagnostics are not required for a diagnosis. Clinical practice guidelines from the American Academy of Otolaryngology-Head and Neck Surgery concur that diagnostic testing is not needed to identify Bell palsy. The guidelines recommend that clinicians should not obtain routine laboratory testing in patients with new-onset Bell palsy, pointing out that this approach is not cost-effective. However, both the rapid evidence review and guidelines state that laboratory testing can help identify systemic causes of facial palsy symptoms, such as Lyme disease or diabetes, when reasonable clinical suspicion exists. Learn more about workup for Bell palsy. Oral corticosteroids are recommended in a rapid evidence review as the first-line treatment for Bell palsy. Guidelines from the American Academy of Otolaryngology-Head and Neck Surgery also recommend this approach in patients age = 16 years with Bell palsy. Antiviral monotherapy has not been demonstrated to influence recovery and should be avoided. However, combination therapy with oral corticosteroids and antivirals should be considered, as this approach consistently results in lower rates of synkinesis and might reduce rates of incomplete recovery. Local injectable anesthetic would not be an appropriate therapy because it would not address the underlying cause, lower motor neuron palsy. There is no evidence-based role for local anesthetic in the treatment of Bell palsy. Electroconvulsive therapy is mostly used in the treatment of severe mood disorders. The mechanism of action would not be expected to be useful in the treatment of facial nerve palsy. Learn more about management of Bell palsy. Along with the Sunnybrook facial grading system, the House-Brackmann scale is widely used to qualify symptom severity of Bell palsy. A patient with obvious facial weakness, inability to move the forehead, incomplete closure of the eyelids, and mouth asymmetry with maximal effort would be grade IV, moderately severe symptoms. Grade I is classified as a normal presentation with full facial function in all areas. Grade II is characterized by slight facial weakness on close inspection, slight synkinesis, and no lagophthalmos. Grade III would exhibit moderate symptoms with noticeable, but not severe, synkinesis; obvious facial asymmetry but not disfiguring; complete eyelid closure with effort; and slightly weak mouth even with maximal effort. Learn more about Bell palsy prognosis.
New York Times
2 hours ago
- New York Times
Quote of the Day: ‘I Feel Like I've Been Lied To': When a Measles Outbreak Hits Home
'It's still spreading. I'm starting to think this thing has come back to stay.' LYNN DOUGLAS, the nursing director of the Williston Basin School District in North Dakota, on an outbreak of measles, a disease that had not been present in the state in 14 years. Measles has also hit other parts of the U.S.
Yahoo
3 hours ago
- Yahoo
I Tried the Japanese Walking Routine Everyone's Talking About—Is It Worth the Hype?
There's no shortage of fitness fads, and the latest one to take over my social media feeds is the Japanese walking trend. The workout is easy, quick, and promises to lower blood pressure—as long as you're consistent—so I tried it for a week to see if it's as good as the fitfluencers say. Essentially, this is a 30-minute high-intensity walking workout. Here's how it works: Do three minutes of fast walking (about 70% of your peak aerobic capacity) Switch to three minutes of slow walking (about 40% of your peak aerobic capacity) Repeat the intervals for a total of 30 minutes Unlike some fitness trends, this workout is backed by science! Researchers created the routine nearly 20 years ago and tested it on adults who were, on average, 63 years old. The study found that adults who completed the walk four days a week had lower blood pressure compared to those who didn't do the workout. The Japanese walking routine has taken off on TikTok, and popular fitness coach Eugene Teo even said it is a great way to get your steps in. I trained for the REAL SIMPLE Women's Half Marathon in 2024 and loved running so much that I kept up with it until a few months ago. Now that I'm out of practice, I can run for a mile (very slowly), so this was a nice way to ease back into things. The faster-paced intervals were long enough that I felt challenged, but not too long that I needed to stop before the time was up. Having the recovery time was nice as I didn't feel as tired as I typically do after a run. However, it took a while for my heart rate to recover enough to reach 40% of my peak aerobic capacity. For example, it sometimes took half of the interval before my heart rate was low enough, but since I felt recovered, I stuck with the three minutes. You do have to keep track of time, meaning you can't zone out! To make it easy, I programmed the routine in my Apple Watch. This way, I got alerts when it was time for a new interval. Compared to other walking workouts, such as the popular 12-30-3 workout, I enjoyed this one much more. (If you don't know, 12-30-3 was a popular treadmill walk where you set the incline at 13, the pace at 3 miles per hour, and move for 30 minutes.) I've found that walking at the same pace for 30 minutes can get boring. But I gave that one another go to see how it compares to the Japanese walking routine in terms of average heart rate and distance. I found that both walking methods produced similar results, according to my watch. Over the week, I noticed the walk became easier, and I had to walk faster to ensure I reached 40% of my peak aerobic capacity. If you're looking to get into running (or get back into running, as in my case), this is a great way to do it! I'll continue to use this as my main form of cardio as I build back up. Plus, it's only 30 minutes, and can be done nearly anywhere. Read the original article on Real Simple
